Drug Information

Drug General Information
Drug ID
D0H1FL
Former ID
DIB005906
Drug Name
PF-514273
Drug Type
Small molecular drug
Indication Obesity [ICD9: 278; ICD10:E66] Discontinued in Phase 1 [548445]
Company
Pfizer Inc
Formula
C21H17Cl2F2N3O2
Canonical SMILES
C1(=O)N(CCOc2c1nn(c2c1ccc(cc1)Cl)c1ccccc1Cl)CC(F)(F)C
PubChem Compound ID
11316919
Target and Pathway
Target(s) Cannabinoid receptor 1 Target Info Modulator [532853]
KEGG Pathway Rap1 signaling pathway
Neuroactive ligand-receptor interaction
Retrograde endocannabinoid signaling
PANTHER Pathway Endogenous cannabinoid signaling
Pathway Interaction Database N-cadherin signaling events
Reactome Class A/1 (Rhodopsin-like receptors)
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Small Ligand GPCRs
BDNF signaling pathway
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 548445Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025584)
Ref 532853Effects of the novel cannabinoid CB1 receptor antagonist PF 514273 on the acquisition and expression of ethanol conditioned place preference. Alcohol. 2014 Aug;48(5):427-31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.